ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Average Price Target of $7.60 According to Brokerages

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have earned a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $7.60.

Several analysts have recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $3.00 target price on shares of ProQR Therapeutics in a report on Thursday, October 1st. HC Wainwright cut their price target on shares of ProQR Therapeutics to $8.00 and set a “buy” rating for the company in a report on Thursday, October 1st. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of ProQR Therapeutics in a research report on Friday.

ProQR Therapeutics Stock Up 3.7%

Shares of NASDAQ PRQR traded up $0.05 during mid-day trading on Thursday, hitting $1.41. 568,539 shares of the company were exchanged, compared to its average volume of 807,538. The stock has a 50 day simple moving average of $1.57 and a 200-day simple moving average of $1.68. ProQR Therapeutics has a 1-year low of $1.20 and a 1-year high of $2.48. The firm has a market cap of $148.56 million, a price-to-earnings ratio of -3.07 and a beta of 0.29.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The company had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $4.30 million. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. Analysts anticipate that ProQR Therapeutics will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of ProQR Therapeutics

A number of institutional investors have recently modified their holdings of the business. Marshall Wace LLP acquired a new position in shares of ProQR Therapeutics during the 3rd quarter worth approximately $1,860,000. RFG Advisory LLC grew its holdings in ProQR Therapeutics by 236.8% during the 2nd quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 45,000 shares during the last quarter. Axiom Investment Management LLC acquired a new stake in ProQR Therapeutics during the 1st quarter valued at $53,000. Alpha Wealth Funds LLC acquired a new stake in ProQR Therapeutics during the 3rd quarter valued at $41,000. Finally, Walleye Capital LLC increased its position in ProQR Therapeutics by 2.7% during the first quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock worth $984,000 after buying an additional 15,744 shares in the last quarter. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a biotechnology company developing RNA-based medicines for genetic diseases. Its research centers on Axiomer, a platform designed to make targeted changes to RNA using the body’s naturally occurring editing machinery. Founded in 2012 and based in Leiden, the Netherlands, ProQR initially focused on RNA therapies for inherited retinal disorders, including Usher syndrome and Leber congenital amaurosis. The company later broadened its emphasis to RNA editing and continues to develop potential treatments for genetic conditions.